Vaxcyte (PCVX)Officer filed to sell ~$1.56M

~$1.56M

planned to sell · 18K shares, around Oct 5, 2026

Planned for

Oct 5, 2026

Notice filed

Oct 5, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Jul 16, 2026CongressDisclosed purchase of PCVX — reported range $1,001 - $15,000
2. Aug 31, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On August 31, 2026, Vaxcyte, Inc. (the “Company”) appointed David McAvoy as the Company's Chief Legal Officer, Chief Compliance Officer, and Corporate Secretary.”
3. Oct 1, 2026Insider · 1 personInsiders: 2 sales (~$128K)
4. Oct 5, 2026Insider · 2 peopleInsiders: 2 sales (~$3.2M)

What came next

1. Oct 6, 2026Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations (and 1 more item)

How to read SEC Form 144

Form 144 is a notice that a company insider plans to sell shares. It is filed when the sell order is placed, so it announces a planned sale and does not prove that the sale took place.

Full guide: What is an SEC Form 144?

What else is on file for Vaxcyte

For Vaxcyte, OQRO holds 6 insider filings (SEC Form 4 or Form 144), 1 Congress trade report and 9 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its PCVX page.

How this filing works

• SEC Form 144
• Rule 10b5-1 trading plans

Other disclosures at Vaxcyte

• SEC Form 4Oct 8, 2026
• SEC Form 4Oct 8, 2026
• SEC Form 144Oct 5, 2026
• SEC Form 4Oct 3, 2026
• SEC Form 4Oct 3, 2026
• House Clerk periodic transaction reportSep 4, 2026

Everything OQRO holds on this company is on its PCVX page.